Literature DB >> 23283551

Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part I--a method of manual documentary analysis.

Nina Ilic1, Snezana Savic, Evan Siegel, Kerry Atkinson, Ljiljana Tasic.   

Abstract

Recent development of a wide range of regulatory standards applicable to production and use of tissues, cells, and other biologics (or biologicals), as advanced therapies, indicates considerable interest in the regulation of these products. The objective of this study was to analyze and compare high-tier documents within the Australian, European, and U.S. biologic drug regulatory environments using qualitative methodology. Cohort 1 of the selected 18 high-tier regulatory documents from the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the Therapeutic Goods Administration (TGA) regulatory frameworks were subject to a manual documentary analysis. These documents were consistent with the legal requirements for manufacturing and use of biologic drugs in humans and fall into six different categories. Manual analysis included a terminology search. The occurrence, frequency, and interchangeable use of different terms and phrases were recorded in the manual documentary analysis. Despite obvious differences, manual documentary analysis revealed certain consistency in use of terminology across analyzed frameworks. Phrase search frequencies have shown less uniformity than the search of terms. Overall, the EMA framework's documents referred to "medicinal products" and "marketing authorization(s)," the FDA documents discussed "drug(s)" or "biologic(s)," and the TGA documents referred to "biological(s)." Although high-tier documents often use different terminology they share concepts and themes. Documents originating from the same source have more conjunction in their terminology although they belong to different frameworks (i.e., Good Clinical Practice requirements based on the Declaration of Helsinki, 1964). Automated (software-based) documentary analysis should be obtained for the conceptual and relational analysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23283551      PMCID: PMC3659669          DOI: 10.5966/sctm.2012-0037

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  13 in total

1.  Ethical issues in the documentary data analysis of Internet posts and archives.

Authors:  J Sixsmith; C D Murray
Journal:  Qual Health Res       Date:  2001-05

2.  Lack of investment in regulatory science is part of "innovation gap," believes FDA commissioner.

Authors:  Elizabeth Sukkar
Journal:  BMJ       Date:  2011-12-08

3.  Good Medical Practice or CanMEDS for education?

Authors:  Trevor Gray; Janet Grant
Journal:  J Clin Pathol       Date:  2012-01-28       Impact factor: 3.411

4.  FDA regulation of stem-cell-based therapies.

Authors:  Dina Gould Halme; David A Kessler
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

5.  Analysis of recent pharmaceutical regulatory documents on analytical method validation.

Authors:  Eric Rozet; Attilio Ceccato; Cédric Hubert; Eric Ziemons; Radu Oprean; Serge Rudaz; Bruno Boulanger; Philippe Hubert
Journal:  J Chromatogr A       Date:  2007-04-01       Impact factor: 4.759

6.  (Re)defining biopharmaceutical.

Authors:  Ronald A Rader
Journal:  Nat Biotechnol       Date:  2008-07       Impact factor: 54.908

7.  Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part II--a method of software documentary analysis.

Authors:  Nina Ilic; Snezana Savic; Evan Siegel; Kerry Atkinson; Ljiljana Tasic
Journal:  Stem Cells Transl Med       Date:  2012-12-04       Impact factor: 6.940

Review 8.  Qualitative environmental health research: an analysis of the literature, 1991-2008.

Authors:  Madeleine Kangsen Scammell
Journal:  Cien Saude Colet       Date:  2011-10

9.  Does the FDA have regulatory authority over adult autologous stem cell therapies? 21 CFR 1271 and the emperor's new clothes.

Authors:  Michael Freeman; Mitchell Fuerst
Journal:  J Transl Med       Date:  2012-03-26       Impact factor: 5.531

10.  Regulatory scientific advice in drug development: does company size make a difference?

Authors:  Michelle Putzeist; Aukje K Mantel-Teeuwisse; Christine C Gispen-De Wied; Arno W Hoes; Hubert G Leufkens
Journal:  Eur J Clin Pharmacol       Date:  2010-11-04       Impact factor: 2.953

View more
  6 in total

Review 1.  Exosomal therapy-a new frontier in regenerative medicine.

Authors:  Sathish Muthu; Asawari Bapat; Rashmi Jain; Naveen Jeyaraman; Madhan Jeyaraman
Journal:  Stem Cell Investig       Date:  2021-04-02

2.  Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part II--a method of software documentary analysis.

Authors:  Nina Ilic; Snezana Savic; Evan Siegel; Kerry Atkinson; Ljiljana Tasic
Journal:  Stem Cells Transl Med       Date:  2012-12-04       Impact factor: 6.940

Review 3.  Concepts in regenerative medicine: Past, present, and future in articular cartilage treatment.

Authors:  Adam W Anz; Asawari Bapat; William D Murrell
Journal:  J Clin Orthop Trauma       Date:  2016-06-15

4.  Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.

Authors:  Thomas Lener; Mario Gimona; Ludwig Aigner; Verena Börger; Edit Buzas; Giovanni Camussi; Nathalie Chaput; Devasis Chatterjee; Felipe A Court; Hernando A Del Portillo; Lorraine O'Driscoll; Stefano Fais; Juan M Falcon-Perez; Ursula Felderhoff-Mueser; Lorenzo Fraile; Yong Song Gho; André Görgens; Ramesh C Gupta; An Hendrix; Dirk M Hermann; Andrew F Hill; Fred Hochberg; Peter A Horn; Dominique de Kleijn; Lambros Kordelas; Boris W Kramer; Eva-Maria Krämer-Albers; Sandra Laner-Plamberger; Saara Laitinen; Tommaso Leonardi; Magdalena J Lorenowicz; Sai Kiang Lim; Jan Lötvall; Casey A Maguire; Antonio Marcilla; Irina Nazarenko; Takahiro Ochiya; Tushar Patel; Shona Pedersen; Gabriella Pocsfalvi; Stefano Pluchino; Peter Quesenberry; Ilona G Reischl; Francisco J Rivera; Ralf Sanzenbacher; Katharina Schallmoser; Ineke Slaper-Cortenbach; Dirk Strunk; Torsten Tonn; Pieter Vader; Bas W M van Balkom; Marca Wauben; Samir El Andaloussi; Clotilde Théry; Eva Rohde; Bernd Giebel
Journal:  J Extracell Vesicles       Date:  2015-12-31

5.  Preclinical Evaluation and Optimization of a Cell Therapy Using Human Cord Blood-Derived Endothelial Colony-Forming Cells for Ischemic Retinopathies.

Authors:  Emma Reid; Jasenka Guduric-Fuchs; Christina L O'Neill; Lynsey-Dawn Allen; Sarah E J Chambers; Alan W Stitt; Reinhold J Medina
Journal:  Stem Cells Transl Med       Date:  2017-11-22       Impact factor: 6.940

Review 6.  Perspectives for Clinical Translation of Adipose Stromal/Stem Cells.

Authors:  Mimmi Patrikoski; Bettina Mannerström; Susanna Miettinen
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.